The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Kishor M. Wasan

School of Health Sciences

British Columbia Institute of Technology

Burnaby

Canada

[email]@interchange.ubc.ca

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • School of Health Sciences, British Columbia Institute of Technology, Burnaby, Canada. 2009 - 2010
  • Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada V6T 1Z3. 2002 - 2009
  • Division of Pharmaceutics and Biopharmaceutics, Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver. 2001 - 2009

References

  1. A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral Leishmaniasis in a murine model. Wasan, E.K., Gershkovich, P., Zhao, J., Zhu, X., Werbovetz, K., Tidwell, R.R., Clement, J.G., Thornton, S.J., Wasan, K.M. PLoS. Negl. Trop. Dis (2010) [Pubmed]
  2. Development and characterization of oral lipid-based amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans. Wasan, E.K., Bartlett, K., Gershkovich, P., Sivak, O., Banno, B., Wong, Z., Gagnon, J., Gates, B., Leon, C.G., Wasan, K.M. Int. J. Pharm (2009) [Pubmed]
  3. Highly effective oral amphotericin B formulation against murine visceral leishmaniasis. Wasan, K.M., Wasan, E.K., Gershkovich, P., Zhu, X., Tidwell, R.R., Werbovetz, K.A., Clement, J.G., Thornton, S.J. J. Infect. Dis. (2009) [Pubmed]
  4. The biological functions of lipid excipients and the implications for pharmaceutical products development. Wasan, K.M. J. Pharm. Sci (2009) [Pubmed]
  5. The global access initiative at the University of British Columbia (UBC): Availability of UBC discoveries and technologies to the developing world. Wasan, K.M., Thornton, S.J., Bell, I., Goulding, R.E., Gretes, M., Gray, A.P., Hancock, R.E., Campbell, B. J. Pharm. Sci (2009) [Pubmed]
  6. Influence of plasma cholesterol and triglyceride concentrations and eritoran (E5564) micelle size on its plasma pharmacokinetics and ex vivo activity following single intravenous bolus dose into healthy female rabbits. Wasan, K.M., Risovic, V., Sivak, O., Lee, S.D., Mason, D.X., Chiklis, G.R., McShane, J., Lynn, M., Wong, N., Rossignol, D.P. Pharm. Res. (2008) [Pubmed]
  7. Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery. Wasan, K.M., Brocks, D.R., Lee, S.D., Sachs-Barrable, K., Thornton, S.J. Nat. Rev. Drug. Discov (2008) [Pubmed]
  8. Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and AmBisome in combination with caspofungin to rats infected with Aspergillus fumigatus. Wasan, K.M., Sivak, O., Rosland, M., Risovic, V., Bartlett, K. J. Pharm. Sci (2007) [Pubmed]
  9. Role of plasma lipids and lipoproteins in predicting amphotericin B-induced nephrotoxicity in pediatric oncology patients. Wasan, K.M., Wong, J.C., Corr, T., Pritchard, S. Cancer Chemother. Pharmacol. (2006) [Pubmed]
  10. Differences in plasma homocysteine levels between Zucker fatty and Zucker diabetic fatty rats following 3 weeks oral administration of organic vanadium compounds. Wasan, K.M., Risovic, V., Yuen, V.G., McNeill, J.H. J. Trace. Elem. Med. Biol (2006) [Pubmed]
  11. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Wasan, K.M., Goss, P.E., Pritchard, P.H., Shepherd, L., Palmer, M.J., Liu, S., Tu, D., Ingle, J.N., Heath, M., Deangelis, D., Perez, E.A. Ann. Oncol. (2005) [Pubmed]
  12. Determining the critical micelle concentration of a novel lipid-lowering agent, disodium ascorbyl phytostanyl phosphate (FM-VP4), using a fluorescence depolarization procedure. Wasan, K.M., Choo, E., Sivak, O., Wallis, S., Letchford, K., Burt, H.M., Stewart, D.J., Lukic, T. Drug. Dev. Ind. Pharm (2004) [Pubmed]
  13. Influence of phytostanol phosphoryl ascorbate (FM-VP4) on insulin resistance, hyperglycemia, plasma lipid levels, and gastrointestinal absorption of exogenous cholesterol in Zucker (fa/fa) fatty and lean rats. Wasan, K.M., Zamfir, C., Pritchard, P.H., Pederson, R.A. J. Pharm. Sci (2003) [Pubmed]
  14. Modifications in lipoprotein surface charge alter cyclosporine A association with low-density lipoproteins. Wasan, K.M., Sivak, O. Pharm. Res. (2003) [Pubmed]
  15. Effects of disodium ascorbyl phytostanol phosphates (FM-VP4) on cholesterol accumulation within rat intestinal cells. Wasan, K.M., Yau, E., Boulanger, K.D., Ramswamy, M., Pritchard, P.H. AAPS. PharmSci (2003) [Pubmed]
  16. Poloxamer 407-mediated alterations in the activities of enzymes regulating lipid metabolism in rats. Wasan, K.M., Subramanian, R., Kwong, M., Goldberg, I.J., Wright, T., Johnston, T.P. J. Pharm. Pharm. Sci (2003) [Pubmed]
  17. Plasma protein binding, lipoprotein distribution and uptake of free and lipid-associated BCL-2 antisense oligodeoxynucleotides (G3139) in human melanoma cells. Wasan, E.K., Waterhouse, D., Sivak, O., Bally, M.B., Klasa, R.J., Wasan, K.M. Int. J. Pharm (2002) [Pubmed]
  18. Effect of cyclosporine A on the binding affinity and internalization of low-density lipoproteins in human skin fibroblasts. Wasan, K.M., Donnachie, E.M., Seccombe, D.W., Pritchard, P.H. J. Pharm. Sci (2002) [Pubmed]
  19. The role of lymphatic transport in enhancing oral protein and peptide drug delivery. Wasan, K.M. Drug. Dev. Ind. Pharm (2002) [Pubmed]
  20. Role of plasma lipoproteins in modifying the toxic effects of water-insoluble drugs: studies with cyclosporine A. Wasan, K.M., Ramaswamy, M., Kwong, M., Boulanger, K.D. AAPS. PharmSci (2002) [Pubmed]
  21. Assessing plasma pharmacokinetics of cholesterol following oral coadministration with a novel vegetable stanol mixture to fasting rats. Wasan, K.M., Holtorf, L., Subramanian, R., Cassidy, S.M., Pritchard, P.H., Stewart, D.J., Novak, E., Moghadasian, M.H. J. Pharm. Sci (2001) [Pubmed]
  22. Formulation and physiological and biopharmaceutical issues in the development of oral lipid-based drug delivery systems. Wasan, K.M. Drug. Dev. Ind. Pharm (2001) [Pubmed]
  23. Assessing the plasma pharmacokinetics, tissue distribution, excretion and effects on cholesterol pharmacokinetics of a novel hydrophilic compound, FM-VP4, following administration to rats. Wasan, K.M., Peteherych, K.D., Najafi, S., Zamfir, C., Pritchard, P.H. J. Pharm. Pharm. Sci (2001) [Pubmed]
  24. Assessing plasma lipid levels, body weight, and hepatic and renal toxicity following chronic oral administration of a water soluble phytostanol compound, FM-VP4, to gerbils. Wasan, K.M., Najafi, S., Wong, J., Kwong, M., Pritchard, P.H. J. Pharm. Pharm. Sci (2001) [Pubmed]
  25. Effects of a novel hydrophilic phytostanol analog on plasma lipid concentrations in gerbils. Wasan, K.M., Najafi, S., Peteherych, K.D., Pritchard, P.H. J. Pharm. Sci (2001) [Pubmed]
 
WikiGenes - Universities